Up Therapeutics, Inc.

Up Therapeutics is a preclinical biotech company developing small molecule Rpn13 inhibitors, a proprietary class of drugs intended to treat cancer patients. The company's approach focuses on leveraging proteasome inhibition technology to improve both the quality and quantity of life for cancer patients.